0000950170-21-004750.txt : 20211118 0000950170-21-004750.hdr.sgml : 20211118 20211118070749 ACCESSION NUMBER: 0000950170-21-004750 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20211117 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211118 DATE AS OF CHANGE: 20211118 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adicet Bio, Inc. CENTRAL INDEX KEY: 0001720580 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813305277 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38359 FILM NUMBER: 211422591 BUSINESS ADDRESS: STREET 1: 200 CLARENDON STREET STREET 2: FLOOR 6 CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 617-482-2333 MAIL ADDRESS: STREET 1: 200 CLARENDON STREET STREET 2: FLOOR 6 CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: resTORbio, Inc. DATE OF NAME CHANGE: 20171024 8-K 1 acet-20211117.htm 8-K 8-K
0001720580false00017205802021-11-172021-11-17

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 17, 2021

 

Adicet Bio, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

001-38359

81-3305277

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 


 

 

200 Clarendon Street, Floor 6

Boston, MA

02116

 

 

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (650) 503-9095

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

ACET

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors

Election of Michael Kauffman, M.D., Ph.D., as Director

On November 17, 2021, upon the recommendation of the Nominating and Corporate Governance Committee (the “NCG Committee”) of the board of directors (the “Board”) of Adicet Bio, Inc. (the “Company”), the Board appointed Michael Kauffman, M.D., Ph.D., to join the Board, effective as of November 17, 2021. Dr. Kauffman will serve as a Class III director until his term expires at the 2024 annual meeting of stockholders at which time he will stand for reelection by the Company’s stockholders. The Board determined that Dr. Kauffman is independent under the listing standards of The Nasdaq Stock Market (“Nasdaq”). Dr. Kauffman was also appointed to serve on the NCG Committee to replace Aya Jakobovits, Ph.D., who resigned from the NCG Committee effective upon Dr. Kauffman’s appointment. The Board has determined that Dr. Kauffman meets the requirements for independence of NCG Committee members under the applicable listing standards of Nasdaq and the Securities Exchange Act of 1934, as amended. Effective as of November 17, 2021, the NCG Committee is composed of Andrew Sinclair, Ph.D. (Chairperson), Steve Dubin and Dr. Kauffman.

As a non-employee director, Dr. Kauffman will receive cash compensation for his Board service in accordance with the Company’s Non-Employee Director Compensation Policy, as amended. In addition, upon his election as a director on November 17, 2021, Dr. Kauffman was granted an option to purchase 37,000 shares of the Company’s common stock at an exercise price per share of $9.39 with the shares vesting and becoming exercisable in thirty-six (36) equal monthly installments commencing on November 17, 2021, subject to the continued service of Dr. Kauffman on the Board. Dr. Kauffman is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K, and there are no arrangements or understandings between Dr. Kauffman and any other persons pursuant to which he was selected as a director. In addition, Dr. Kauffman has entered into an indemnification agreement with the Company consistent with the form of indemnification agreement entered into between the Company and its existing non-employee directors.

Item 7.01 Regulation FD Disclosure

On November 18, 2021, the Company issued a press release announcing Dr. Kauffman’s appointment to the Board. A copy of this press release is furnished as Exhibit 99.1 to this report on Form 8-K.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit

Number

 

Description

99.1

 

Press Release furnished by the Company on November 18, 2021.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL Document).

 


 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

ADICET BIO, INC.

 

 

 

 

Date: November 18, 2021

 

By:

/s/ Nick Harvey

 

 

Name:

Nick Harvey

 

 

Title:

Chief Financial Officer

 

 

 EX-99.1 2 acet-ex99_1.htm EX-99.1 EX-99.1

 

Adicet Announces Appointment of Dr. Michael G. Kauffman to the Board of Directors

Menlo Park, CA and Boston, MA – November 18, 2021 – Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Michael G. Kauffman M.D., Ph.D., to its Board of Directors.

"Dr. Kauffman’s appointment brings a wealth of expertise to our board and will be invaluable as we advance the development of our pipeline of next-generation off-the-shelf, gamma-delta CAR-T therapies," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "Dr. Kauffman is an industry veteran with considerable experience in oncology drug development and, notably, has been instrumental in the approval of several oncology drugs. We look forward to benefiting from Michael’s expertise and insights."

Dr. Kauffman joins the Adicet board with over 20 years of experience in the life sciences industry, including expertise in preclinical research, clinical development and regulatory strategy. Currently, he is a board member for Karyopharm Therapeutics, Verastem Oncology and Kezar Life Sciences. Most recently, Dr. Kauffman served as the co-founder and chief executive officer of Karyopharm, where he guided the Company’s transition from a discovery stage biotechnology company to a commercial stage organization. Prior to joining Karyopharm, Dr. Kauffman was Chief Medical Officer of Onyx Pharmaceuticals Inc., which acquired Proteolix Inc. Previously, Dr. Kauffman was President and Chief Executive officer of EPIX Pharmaceuticals, Inc. (previously Predix Pharmaceuticals, Inc.). Before that, he was the leader of the Velcade® development program at Millennium Pharmaceuticals, and has also held a number of senior positions at Millennium Predictive Medicine and Biogen. Dr. Kauffman received his M.D. and Ph.D. from Johns Hopkins Medical School and is board certified in Internal Medicine.

“Adicet’s leading gamma delta CAR-T cell platform is unique in that it is designed to leverage the inherent innate and adaptive ability of gamma delta T cells to complement a chimeric antigen receptor for enhanced tumor killing,” said Kauffman. “If successful in the clinic, these three anti-tumor mechanisms could provide significant benefits over current cell therapy platforms, without the need for gene editing. I look forward to working closely with the team to advance Adicet’s pipeline of off-the-shelf, CAR-T therapies for the treatment of cancer and other diseases.”

About Adicet Bio, Inc.

Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.

Forward-Looking Statements

This press release contains "forward-looking statements" of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to business and operations of Adicet including, but not limited to the contributions resulting from members of the board of directors, future plans or expectations around Adicet’s CAR-T cell platform as well as the expected potential therapeutic effects of drug candidates, expectations regarding the initiation, design, implementation, timing, and success of future clinical studies and expectations regarding its other CAR gamma delta T cell therapy development activities.

 

 

Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, the effect of COVID-19 on our business and financial results, including with respect to disruptions to our clinical trials, business operations, and ability to raise additional capital; and Adicet's ability to execute on its strategy. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Adicet's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in Adicet's most recent annual report on Form 10-K and our periodic reports on Form 10-Q and Form 8-K filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Adicet's other filings with the SEC. All information in this press release is as of the date of the release, and Adicet undertakes no duty to update this information unless required by law.

 

Adicet Bio, Inc.

Investor and Media Contacts

Anne Bowdidge

abowdidge@adicetbio.com

 

Janhavi Mohite

Stern Investor Relations, Inc.

212-362-1200

janhavi.mohite@sternir.com

 

 EX-101.LAB 3 acet-20211117_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Health Care Organizations [Abstract] Entity Central Index Key Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 4 acet-20211117_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 5 acet-20211117.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink XML 6 acet-20211117_htm.xml IDEA: XBRL DOCUMENT 0001720580 2021-11-17 2021-11-17 0001720580 false 8-K 2021-11-17 Adicet Bio, Inc. DE 001-38359 81-3305277 200 Clarendon Street Floor 6 Boston MA 02116 650 503-9095 false false false false Common Stock, par value $0.0001 per share ACET NASDAQ true false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Nov. 17, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 17, 2021
Entity Registrant Name Adicet Bio, Inc.
Entity Central Index Key 0001720580
Entity Incorporation State Country Code DE
Entity File Number 001-38359
Entity Tax Identification Number 81-3305277
Entity Address, Address Line One 200 Clarendon Street
Entity Address, Address Line Two Floor 6
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02116
City Area Code 650
Local Phone Number 503-9095
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol ACET
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( /@XQLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #X.')3 A&I9>\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)OI^GZC]#-1?&D(+B@> O)[&ZP:4(RTN[;F\;=+J(/(.22F5^^ M^0;2Z2"TC_@W0JU3DQY.;61Z% "7C-@WI\:6L6]DA MD1HTYE?)"CH$7+/3Y-?5W?WF@%W%G;>V*W] MQ\8G0=G!KW\AOP!02P,$% @ ^#AR4YE&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" #X.')3*OH.AE<$ !S$0 & 'AL+W=O_0L/T,L&V"%\[A!E"2)O9398&VIUIIQ?"%J");'DE.9!_ MWR,;;)J:8Z8W8!F?UX_.D5Y)C'9*OYHMYY;L8YF8V];6VO2SYYEPRV-FVBKE M"?RR5CIF%IIZXYE4Y??F>CQ2F94BX7--3!;'3+_? M<:EVMZV@=;SQ(C9;ZVYXXU'*-GS![>_I7$/+*U4B$?/$")40S=>WK4GP^8[V M7$#^Q!^"[\S)-7%=62GUZAJ/T6W+=T1<\M Z"09?;WS*I71*P/'C(-HJW^D" M3Z^/Z@]YYZ$S*V;X5,GO(K+;V]:@12*^9IFT+VKW*S]TJ.OT0B5-_DEVQ;,W M?HN$F;$J/@0#02R2XIOM#XDX#:!G N@A@.;>!"\ M*P3I&<%G]=8F0?^*4)\&_P[W@*T$I"4@S?4Z9_2FZHUK\M=D9:R&$OZ-2'9* MR4XN>=/4Y^5[RNMZB(9 M1"($@[L3Z@H&=]A&T/HE6O\2M"ED3C,)JA'?DR_\O0X.5_)]/^A3OSOP$:Q! MB36X! LZJ72J=#Z'R<)"/_(802W%6H1%TL[S-4@.@*_C=VF_CQ&> M^'-P">$DBC0WYNIX0;["<^1;4EO*!DE8L%/7 O6EVM4O=+C MS5/Z+-H==@>'^*]*R3-"C"VA"@!:V6AP#W M];R $]B,GD?!!7I=S'2#:C$(< __JD+(R7RK$LS8&D2Z?N=ZZ ^[&%&U#@2X M7W_7PEJ>0&+B.$L.IF9JJ7"AIGU&4)E_@#OW0DD1"BN2#7F"X:T%D[4\N$H3 M#ZV\G^)&/=<\3P^'^55L!\$08:_Y;;VNKU^#7B-9Y?D4-^C_D#T:DP%9(R N MVPAXLB?'77G!PTR[R1?0%5D**VLG7X.(ZV&^_JCP]8JD3),W)C-.?O;;;D]$ M4NBJV<(RA2%7YD]QMUYJ%KFAMWB/5ZIVX#4(3*:S)492F3W%C;E,WFP?;EFR MX6=WM0U"SY/%_>0WC*ER>7J1R\]BKCM$98+8G4,'$B'QS5IQ5:K%PM;-3P#LY0KN_(YZ82X0ADJ]!R&_WH;NZ..$7 M#:O2_%2]4A;.Z/GEEC.8GNX!^'VME#TVW$&]_)]E_ ]02P,$% @ ^#AR M4Y^@&_"Q @ X@P T !X;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)J MXI$8MD!AL(U"\V%?E5AV!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN M6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9 MWMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+ ME)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64 M,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8). MIF(M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5B'_2^ MFO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0)P:?EA M6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q]%PZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\ M3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4 MKS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0ERHY_U=3_ 10 M2P,$% @ ^#AR4Y>*NQS $P( L !?3T\$MP>:4#M M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3 MY?YVX$G1H2)8%II%R=.B':5_'FR-9V87YTC'?8Q']>5=2(6NF9MYEJ6R!F_236P@R*2*Y U+2X3[+O,&@EXN1:T/9=1,92L88!.R '<(Y_A M^[<#K3P&]'@!6^AC(,=D",Y1]XVXG\-/O4(VSV M'T:$%'J6"V&%E+C?Z/F-:#R!+ ]=R_$)'0.M#,,SQ;;!<.AHQ$5V9://8:Q# MB'/Z3XRQJK"$52Q;#X&'' E<)S"D&IND53 >"CVN*!.L>@PL(:EU&*ADMW,J MI]=V<,TB]RI#FJ,,:&T'X:-:"Q4&L&]R( DNR94;4EWI>::W=Y-[2:AU[D&P M]_ :C1W-CQ^W_ %02P,$% @ ^#AR4R0>FZ*M ^ $ !H !X;"]? M+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2* M+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\ M7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7 M-_=%KLWC":[?#'!X=/X!4$L#!!0 ( /@X-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB M>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9 M/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1 MB5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9 M_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D\ K @ $0 @ &O M 9&]C4')O<',O8V]R92YX;6Q02P$"% ,4 " #X.')3F5R<(Q & "< M)P $P @ '- 0 >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 M Q0 ( /@X&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0 M2P$"% ,4 " #X.')399!YDAD! #/ P $P @ &Q$@ I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" #[$P ! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.adicetbio.com/20211117/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports acet-20211117.htm acet-20211117.xsd acet-20211117_lab.xml acet-20211117_pre.xml acet-ex99_1.htm http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "acet-20211117.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "acet-20211117.htm" ] }, "labelLink": { "local": [ "acet-20211117_lab.xml" ] }, "presentationLink": { "local": [ "acet-20211117_pre.xml" ] }, "schema": { "local": [ "acet-20211117.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "acet", "nsuri": "http://www.adicetbio.com/20211117", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "acet-20211117.htm", "contextRef": "C_5f10303f-a579-4eb4-99cd-02cd16d5d839", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.adicetbio.com/20211117/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "acet-20211117.htm", "contextRef": "C_5f10303f-a579-4eb4-99cd-02cd16d5d839", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adicetbio.com/20211117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adicetbio.com/20211117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adicetbio.com/20211117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adicetbio.com/20211117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adicetbio.com/20211117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adicetbio.com/20211117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adicetbio.com/20211117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adicetbio.com/20211117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adicetbio.com/20211117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adicetbio.com/20211117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adicetbio.com/20211117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adicetbio.com/20211117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adicetbio.com/20211117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adicetbio.com/20211117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adicetbio.com/20211117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adicetbio.com/20211117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adicetbio.com/20211117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adicetbio.com/20211117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adicetbio.com/20211117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adicetbio.com/20211117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adicetbio.com/20211117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adicetbio.com/20211117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adicetbio.com/20211117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adicetbio.com/20211117/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 14 0000950170-21-004750-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-21-004750-xbrl.zip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